• Publications
  • Influence
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
A Second Act for Antiandrogens Men with advanced prostate cancer are often treated with antiandrogens; drugs that inhibit the activity of male hormones, such as testosterone, that help drive tumorExpand
  • 1,627
  • 113
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PURPOSE To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. METHODS A committeeExpand
  • 1,679
  • 83
  • Open Access
Enzalutamide in metastatic prostate cancer before chemotherapy.
BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed afterExpand
  • 1,655
  • 72
  • Open Access
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
BACKGROUND MDV3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of theExpand
  • 904
  • 44
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,
BACKGROUND Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab after radiotherapyExpand
  • 821
  • 26
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
Acquired resistance to anticancer treatments is a substantial barrier to reducing the morbidity and mortality that is attributable to malignant tumors. Components of tissue microenvironments areExpand
  • 494
  • 21
  • Open Access
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
BACKGROUND This phase I/II study in patients with metastatic castration-resistant prostate cancer (mCRPC) explored ipilimumab as monotherapy and in combination with radiotherapy, based on theExpand
  • 402
  • 17
A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
Adenocarcinomas of the prostate can be categorized into tumor grades based on the extent to which the cancers histologically resemble normal prostate glands. Because grades are surrogates ofExpand
  • 253
  • 12
  • Open Access
HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia*
Background: HIF1α is a target of anticancer therapy. Results: Lysines within the HIF1α N terminus are targets of HDAC4 deacetylation. HDAC4 inhibition causes the increase of HIF1α protein acetylationExpand
  • 115
  • 12
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.
PURPOSE Adverse events in chemotherapy clinical trials are assessed and reported by clinicians, yet clinician accuracy in assessing symptoms has been questioned. We compared patient reporting ofExpand
  • 333
  • 11